A Phase 1/2a, Open Label, Dose Escalation, Safety Study of Intra-thrombus Plasmin (Human) Administration in Acute, Middle Cerebral Artery, Ischemic Stroke

This study tests the drug, Plasmin (Human), in patients with a stroke due to a clot in the middle cerebral artery (MCA). Plasmin is an enzyme that causes clot lysis by cleaving a clot component, fibrin. In this study, Plasmin (Human) is administered locally through a catheter to the clot within 9 hours of the stroke onset. Three doses of Plasmin (Human) (20 mg, 40 mg, and 80 mg) are being tested in 3 different groups of patients. Patients are monitored by imaging of the affected artery and functional testing.

开始日期2009-11-01

申办/合作机构

Grifols Therapeutics, Inc.

NCT00418483

/ Completed临床1期

A Sequential Phase I/II Dose Escalation and Dose Selection Safety Study of Regional Intra-thrombus Plasmin (Human) Infusion In Acute Lower Extremity Native Artery or Bypass Graft Occlusion

The purpose of this study is to evaluate the safety of increasing doses of intra-thrombus Plasmin (Human) in acute peripheral arterial occlusion (aPAO). The ability of these Plasmin doses to dissolve the clots will be estimated by arteriography.

开始日期2007-03-01

申办/合作机构

Grifols Therapeutics, Inc.

100 项与 Human plasma-derived fibrinolysin (Grifols) 相关的临床结果

登录后查看更多信息

100 项与 Human plasma-derived fibrinolysin (Grifols) 相关的转化医学

登录后查看更多信息

100 项与 Human plasma-derived fibrinolysin (Grifols) 相关的专利（医药）

登录后查看更多信息

358

项与 Human plasma-derived fibrinolysin (Grifols) 相关的文献（医药）

2025-04-01·CYTOTHERAPY

Robust differentiation and potent immunomodulation of human mesenchymal stromal cells cultured with a xeno-free GMP protein supplement

Article

作者: Seriola, Anna ; Belda, Francisco ; Ojosnegros, Samuel ; Sesma-Herrero, Eduardo ; Oliver-Vila, Irene

BACKGROUND/AIMS:

Human mesenchymal stromal cells (hMSC) are multipotent adult cells commonly used in regenerative medicine as advanced therapy medicinal products. The expansion of these cells in xeno-free supplements is highly encouraged by regulatory agencies due to safety concerns. However, the number of supplements with robust performance and consistency for hMSC expansion are limited. Here, we evaluate a xeno-free human plasma-derived protein supplement (Plastem, Grifols) for the expansion and functional evaluation of hMSCs.

METHODS:

hMSC from bone marrow, adipose tissue and umbilical cord were obtained from two suppliers and cultured in Dulbecco's modified Eagle's medium (DMEM/F-12) supplemented with fetal bovine serum 10% (FBS), human platelet lysate 5% (hPL) or Plastem 10%+ hPL0.5%. Cell proliferation was evaluated after culturing hMSC for 13 days with trypan blue exclusion. hMSC immunophenotype was assessed by flow cytometry of surface markers expression. Multipotentiality assay determined the ability of hMSC to differentiate into osteogenic, chondrogenic and adipogenic lineages after 21 days, by using specific staining. Immunomodulatory properties of hMSC were analyzed by measuring suppression of human peripheral blood mononuclear cell (PBMC) proliferation in co-culture with hMSC.

RESULTS:

Plastem 10% + hPL 0.5% supported robust and sustained hMSC growth with a similar efficiency to the reference supplement FBS 10%. hMSC cultured with the xeno-free supplement presented a similar morphology comparable to FBS-supplemented cells and maintained typical expression of markers: positive (>95%) for CD90, CD73 and CD105; and negative (<5%) for CD45, CD14, CD19, CD34 and HLA-DR. Likewise, hMSC showed potent, in vitro differentiation potential into osteogenic, chondrogenic and adipogenic lineages, outperforming the results obtained with traditional reference supplements in several instances. They retained their immunomodulatory properties, inhibiting the proliferation of phytohemagglutinin (PHA)-stimulated PBMCs with a notable enhancement of the immunomodulatory capacity of hMSCs compared to conventional reference supplements.

CONCLUSIONS:

Plastem allowed hMSC expansion while preserving phenotype and showed remarkable differentiation and immunomodulatory properties, supporting its use for cell therapy manufacturing processes as a robust, xeno-free alternative to FBS and hPL. Moreover, Plastem can be manufactured at an industrial level, making it a scalable solution for widespread application.

2024-11-01·JOURNAL OF PEDIATRIC SURGERY

A Phase 3, Randomized, Active-controlled, Single-blind Clinical Trial to Evaluate the Efficacy of Fibrin Sealant Grifols in Achieving Hemostasis in Pediatric Surgery

Article

作者: Balanescu, Laura ; Slavkovic, Andjelka ; Camprubí, Sandra ; Hanna, Kim ; James, Michael K. ; Jenovari, Zoltan ; Querolt, Montse ; Gajdobranski, Djordje ; Mikickovic, Maja ; Bozzo, Jordi ; Camprubí, Sandra ; Vajda, Péter ; Kamenov, Krasimir ; Querolt, Montse ; Irtan, Sabine ; Mondou, Elsa ; Mondou, Elsa ; Kalinova, Krasimira ; Ninov, Borislav ; Sharif, Khalid ; Simeonov, Simeon ; Sretenović, Aleksandar ; Wiener, Isodoro ; Hanna, Kim

BACKGROUND:

In this study, two fibrin sealant products, Fibrin Sealant Grifols (FS Grifols 80 mg/mL fibrinogen; 500 IU/mL thrombin) and Evicel (fibrinogen 55-85 mg/mL; thrombin 800-1200 IU/mL) were studied for efficacy in achieving hemostasis at a targeted bleeding site (TBS) on parenchymous or soft tissue in pediatric surgeries.

METHODS:

This phase 3, single-blind, active comparator, non-inferiority trial compared the number of patients achieving hemostasis at a TBS at four (T₄ - primary endpoint), seven (T₇) and 10 (T₁₀) minutes after application, Safety and tolerability were assessed by recording adverse events during and after procedures. Eligible patients were <18 years old undergoing elective, open, non-cardiac thoracic, abdominal or pelvic surgeries. Preterm (<37 weeks gestation) and newborn (0-27 days) infants were eligible.

RESULTS:

At T₄, 98.7% of FS Grifols group (n = 91) and 95.4% of the Evicel group (n = 87) achieved hemostasis. All patients with residual bleeding at T₄ were undergoing soft tissue surgery. All patients achieved hemostasis by T₇. At T₁₀, all patients achieved hemostasis except one (FS Grifols (no observation recorded)). There were no incidents of persistent bleeding. For FS Grifols, 26.5% of patients had treatment-emergent adverse events (TEAEs) and 18.4% for Evicel. One TEAE (moderate procedural pain - FS Grifols group) was considered possibly related to study treatment. Three patients died for reasons unrelated to the study medications.

CONCLUSIONS:

FS Grifols was safe and effective at achieving hemostasis in pediatric patients having parenchymous or soft tissue surgeries. The efficacy of FS Grifols was non-inferior to Evicel.

LEVEL OF EVIDENCE:

2024-10-01·Translational Vision Science & Technology

Method for Quantitative Analysis of Vitreoretinal Adhesion in Ex Vivo Model

Article

作者: Suresh, Tara ; Keller, Will ; Ong, Lauren ; Schwartz, Dan ; Brodie, Frank ; Marotta, Christopher B.

Purpose:

Posterior vitreous detachment (PVD) is implicated in numerous retinal pathologies. A necessary step in developing new therapies, an area of significant interest, is a quantifiable assessment of posterior vitreous adhesion (PVA) that is also clinically relevant.

Methods:

A 23-gauge vitrector was used at varying levels of vacuum to attempt PVD induction in a porcine eye model injected with either balanced salt solution (BSS) (control) or plasmin (2, 3, or 5 U), which can pharmacologically induce PVD.

Results:

The average minimum vacuum necessary to induce a PVD was 395 ± 28 mm Hg for BSS alone, 385 ± 58 mm Hg for 2 U of plasmin, 265 ± 53 mm Hg for 3 U of plasmin, and 145 ± 28 mm Hg for 5 U of plasmin. We demonstrated a dose-dependent response curve with increasing amounts of plasmin, leading to a statistically significantly lower minimum vacuum necessary to induce a PVD except between BSS and 2 U plasmin.

Conclusions:

A dose-dependent relationship between plasmin concentration and PVD was demonstrated. We believe that this model offers significant benefits over prior work as it minimizes confounding manipulations and offers a quantitative assessment that is translatable to in vivo surgical models.

Translational Relevance:

This is the first methodology to quantitatively assess the degree of vitreous adhesion in situ.

项与 Human plasma-derived fibrinolysin (Grifols) 相关的新闻（医药）

2025-11-17

·EINPresswire

Albumin Market Size Set for Rapid Expansion, Valued at USD 8.95 Billion by 2030 Driven by Impressive 6.4% CAGR

Significant surge in non-therapeutic application of albumin, increasing production of immunoglobulins & plasma collection is expected to drive the growth PORTLAND, OR, UNITED STATES, November 17, 2025 / EINPresswire.com / -- The prevalence of diseases and life-threatening conditions such as hypoalbuminemia, burns, trauma, liver cirrhosis, and cardiac surgeries significantly propel the growth of the albumin market. The surge in shock and burn cases is anticipated to drive demand for albumin, particularly as a vital volume expander during burn shock resuscitation and for correcting hypoalbuminemia. According to the World Health Organization (WHO), an alarming statistic reveals that approximately 11 million individuals endure burn wounds annually. This underscores the critical role albumin plays in addressing the medical consequences of such incidents. The market's growth is closely tied to its indispensability in therapeutic interventions, especially in scenarios involving trauma, burns, and shock, highlighting its crucial role in modern healthcare. Allied Market Research has published a study report with the title Albumin Market Size was Valued at ๐๐๐ ๐.๐๐ ๐๐ข๐ฅ๐ฅ๐ข๐จ๐ง ๐ข๐ง ๐๐๐๐, and is Anticipated to Garner ๐๐๐ ๐.๐๐ ๐๐ข๐ฅ๐ฅ๐ข๐จ๐ง ๐๐ฒ ๐๐๐๐, registering a ๐๐๐๐ ๐จ๐ ๐.๐% from 2021 to 2030. The report provides an extensive analysis of changing market dynamics, major segments, value chain, competitive scenario, and regional landscape. This research offers a valuable guidance to leading players, investors, shareholders, and startups in devising strategies for sustainable growth and gaining competitive edge in the market. ๐๐๐ญ ๐๐๐๐ ๐๐๐ฆ๐ฉ๐ฅ๐ ๐๐๐ ๐๐๐ฉ๐จ๐ซ๐ญ ๐ฐ๐ข๐ญ๐ก ๐๐ซ๐๐ฉ๐ก๐ฌ ๐๐ง๐ ๐๐ข๐ ๐ฎ๐ซ๐๐ฌ ๐๐๐ซ๐: https://www.alliedmarketresearch.com/request-sample/2583 ๐๐จ๐ฉ ๐๐ฅ๐๐ฎ๐ฆ๐ข๐ง ๐๐จ๐ฆ๐ฉ๐๐ง๐ข๐๐ฌ โข Takeda Pharmaceuticals Inc โข Thermo Fisher Scientific โข Ventria Bioscience โข Baxter International Inc. โข China Biologic Products, Inc. โข Merck KGaA โข Novozymes โข Octapharma AG โข CSL Limited โข Grifols, S.A. ๐๐ฅ๐๐ฎ๐ฆ๐ข๐ง ๐๐๐ซ๐ค๐๐ญ ๐๐๐ ๐ฆ๐๐ง๐ญ๐๐ญ๐ข๐จ๐ง: - The global albumin market is analysed across type, application and region. By type, the human serum albumin segment dominated the market in 2022, accounting for almost two-thirds of the global albumin market and is expected to register highest CAGR of 6.5% during the forecast period owing to the widespread use and diverse applications of human serum albumin in various medical interventions. As a critical component of blood plasma, human serum albumin finds extensive utilization in therapeutic treatments, including fluid resuscitation, wound healing, and the management of hypoalbuminemia. Its compatibility. By application, the therapeutics segment dominated the market in 2022, accounting two-fifths of the global albumin market and is expected to register highest CAGR of 6.7% during the forecast period. This is attributed to the increasing recognition of albumin's therapeutic benefits across diverse medical applications. Its role in addressing critical health challenges such as liver diseases, trauma, and surgical interventions and ability to maintain fluid balance, transport crucial substances, and mitigate protein deficiencies underscores its significance in therapeutic treatments. In addition, ongoing R&D efforts continue to unveil new therapeutic applications for albumin, further propelling its demand. By sales channel, the B2B segment dominated the market in 2022, accounting almost three-fifths of the global albumin market, owing to increased collaborations and partnerships among pharmaceutical and biotech companies. The B2B model facilitates bulk purchases, ensuring a steady supply of albumin for research, manufacturing, and development activities, thus driving market growth.โฏHowever, the B2C segment is expected to register highest CAGR of 6.7% during the forecast period owing to direct sale of products from a business (such as pharmaceutical and biotech companies) to individual consumers or end-users. This approach enhances market accessibility, fosters customer engagement, and potentially leads to increased sales and market share, as businesses establish direct connections with end-users in the dynamic albumin market.โฏ By region, North America held the highest market share in terms of revenue in 2022, accounting for more than two-fifths of the global albumin market revenue, owing to growing access to advanced technologies and a well-developed network of healthcare & research facilities. In addition, the growing aging population and high incidence of diseased conditions owing to surgical interventions, contribute to the sustained demand for albumin products. However, the Asia-Pacific segment is projected to register highest CAGR of 7.0% during the forecast period owing to increasing healthcare infrastructure development, rising awareness about albumin applications, a surge in surgical procedures, and growing initiatives taken by key players by adopting new strategies. ๐๐ฎ๐ซ๐๐ก๐๐ฌ๐ ๐ญ๐ก๐ ๐๐๐ฉ๐จ๐ซ๐ญ: https://www.alliedmarketresearch.com/purchase-enquiry/2583 Key Findings of The Study โข By type, the human serum albumin segment was the highest contributor to the market in 2020. โข On the basis of application type, the therapeutics segment dominated the market in 2020, and is expected to continue this trend during the forecast period. โข Region-wise, North America garnered the largest revenue share in 2020, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period. ๐๐ฎ๐ซ ๐๐๐ซ๐ค๐๐ญ ๐๐๐ฌ๐๐๐ซ๐๐ก ๐๐จ๐ฅ๐ฎ๐ญ๐ข๐จ๐ง ๐๐ซ๐จ๐ฏ๐ข๐๐๐ฌ ๐๐จ๐ฎ ๐๐ง๐ฌ๐ฐ๐๐ซ ๐ญ๐จ ๐๐๐ฅ๐จ๐ฐ ๐๐๐ง๐ญ๐ข๐จ๐ง๐๐ ๐๐ฎ๐๐ฌ๐ญ๐ข๐จ๐ง: โข Which are the driving factors responsible for the growth of market? โข Which are the roadblock factors of this market? โข What are the new opportunities, by which market will grow in coming years? โข What are the trends of this market? โข Which are main factors responsible for new product launch? โข How big is the global & regional market in terms of revenue, sales and production? โข How far will the market grow in forecast period in terms of revenue, sales and production? โข Which region is dominating the global market and what are the market shares of each region in the overall market in 2022? โข How will each segment grow over the forecast period and how much revenue will these segments account for in 2030? โข Which region has more opportunities? ๐๐ฒ ๐๐๐ ๐ข๐จ๐ง ๐๐ฎ๐ญ๐ฅ๐จ๐จ๐ค โข North America (U.S., Canada, Mexico) โข Europe (Germany, France, UK, Italy, Spain, Rest of Europe) โข Asia-Pacific (Japan, China, India, Rest of Asia-Pacific) โข LAMEA (Brazil, Saudi Arabia, South Africa, Rest of LAMEA) ๐๐จ๐ง๐ญ๐๐๐ญ ๐๐๐ญ๐๐ข๐ฅ๐ฌ: David Correa USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022 help@alliedmarketresearch.com ๐๐๐จ๐ฎ๐ญ ๐๐ฌ Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of โMarket Research Reportsโ and โBusiness Intelligence Solutions.โ AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain. David Correa Allied Market Research + 1 800-792-5285 email us here Visit us on social media: LinkedIn Facebook YouTube X Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

2025-04-08

·Business Wire

IBL International collaborates with Grifols on advanced biomarker panels

MÄNNEDORF, Switzerland--(BUSINESS WIRE)--IBL International GmbH, a Tecan company, which develops, manufactures and offers specialty diagnostics, today announced a strategic partnership with Grifols, a global healthcare company and leading producer of plasma-derived medicines and innovative diagnostic solutions, to transform the specialty diagnostics market. Under this collaboration, IBL will develop biomarker panels for specialty diagnostics based on Grifols’ random access, single molecule counting (SMC) platform. These panels will address key customer needs in specialty diagnostics, offering solutions for laboratories and patients alike. The agreement includes a framework for product development, manufacturing and commercialization, ensuring a reliable and efficient delivery to the market. The project brings together IBL’s expertise in specialty diagnostic assay development and Grifols’ leadership in diagnostic instrumentation to produce a state-of-the-art system. The collaboration encompasses: Development of biomarker panels by IBL, tailored for random access on the SMC Platform. Manufacturing and supply of these products by IBL under a master supply agreement. Achieving better specialty diagnostics Specialty diagnostics are often performed outside the high-throughput, automated workflows of the core laboratory, requiring specialized equipment and processes to handle low-volume, high-value tests. This partnership streamlines these processes by combining multiple specialty diagnostic parameters into a single workflow. Grifols’ random access technology allows laboratories to process tests as soon as samples arrive, eliminating delays associated with batching and enabling faster, more efficient diagnostics that enhance patient care. “Partnering with Grifols allows us to scale healthcare innovation globally,” said Mukta Acharya, Head of Tecan’s Life Sciences Business. “By leveraging IBL’s entrepreneurial spirit and technological expertise, we’re addressing unmet needs in specialty diagnostics. Together, we’re creating solutions that empower laboratories and enhance patient journeys with reliable and sensitive diagnostics.” “Our collaboration with IBL demonstrates our commitment to our strategic plan for developing innovative clinical diagnostic solutions,” added Guillermo Marco-Gardoqui, SVP Diagnostic Operations and Strategy at Grifols. “By integrating IBL’s biomarker panels with the advanced capabilities of the SMC Platform, we are enhancing clinical workflows and addressing critical gaps in patient care.” Driving innovation The panels under development respond to customer feedback, ensuring they meet the needs of both laboratories and patients. This first-in-class random access system with SMC technology introduces a clinical market solution that integrates seamlessly into the core lab, enhancing workflow efficiency and allowing for ultra-highly sensitive, multiplexed assays. The partnership demonstrates Tecan’s commitment to improving people’s lives and health by enabling customers to scale healthcare innovation globally. It highlights IBL’s leading position in specialty diagnostics and reflects Tecan’s commitment to advancing modern, multiplexed diagnostic solutions.

诊断试剂

2025-02-18

·FierceBiotech

Grifols, through pioneering plasma research, looks to reveal early warning signs of Parkinson\'s

None\n Written by: GrifolsNearly one million people in the U.S. and more than six million people worldwide have Parkinson\'s disease (PD), a debilitating neurological condition characterized by progressive motor and non-motor symptoms that significantly affects patients and their loved ones.PD occurs when brain cells producing dopamine – a chemical essential for coordinating movement – are damaged. While current diagnostic methods combining medical history, physical examinations and brain imaging can identify the disease, diagnosis often comes after significant neurological deterioration has occurred.This makes the search for early detection biomarkers one of the most pressing needs in Parkinson\'s research, not least because it could enable intervention before the condition worsens.In response, Grifols, a global leader in plasma science and the production of plasma-derived medicines, has embarked on a groundbreaking program in partnership with The Michael J. Fox Foundation for Parkinson\'s Research (MJFF), an organization that has contributed more than $2 billion to advance the understanding and management of Parkinson\'s.Searching for key biomarkersThe research program, named Chronos-PD, aims to identify early biomarkers of Parkinson\'s disease through the analysis of longitudinal plasma samples, with the potential to transform how the condition is detected and treated. Scientifically, this initiative is based on the fact that the composition and concentration of people’s plasma shifts over time with age and illness, changes that provide valuable clues about their present and future health.These samples are part of Grifols’ extensive plasma repository, which contains more than 100 million specimens collected over nearly 15 years. Their medical value is in their link to real-world health data revealing illnesses like PD that were diagnosed years after the plasma was collected. Each sample is a mini time capsule, collectively capturing the progression of diseases long before diagnosis and even prior to the first symptoms appearing.Through Chronos-PD, Grifols is analyzing a select group of thousands of these samples spanning up to a decade to track the evolution of plasma proteins in individuals who at some point later in life developed PD. The sheer scale and longitudinal nature of the PD sample collection offer a unique opportunity to study progression patterns in PD that would be difficult to observe through other research methods. “The goal of Chronos-PD is to gain a deep molecular understanding of the evolution of the plasma proteome to help identify the early signs of disease and inform the development of diagnostics and therapies. The extensive historical sample repository we have today at Grifols sets us apart from other initiatives. What we do with these samples is combine the molecular information we can obtain from them with health-status data to go back in time and identify the early signs of diseases that developed later.”Scott Lohr , Senior Vice President, Informatics for Chronos, Alkahest (Grifols)Advanced analysis: Combining AI and plasma scienceJust as Grifols revolutionized plasma collection through the development of plasmapheresis in the 1950s (a technique that enables donations of only plasma), and for decades has been a leading provider of trusted medicines derived from plasma proteins such as immunoglobulin and albumin, the company’s researchers are now pioneering new ways to unlock the potential of plasma science for early disease management. Their understanding of the complexities of plasma proteins and their behaviour are crucial for identifying reliable biomarkers. This expertise, combined with the company’s advanced analytical capabilities, positions Grifols to make meaningful contributions to Parkinson\'s research.Grifols’ Alkahest subsidiary will lead this initiative, applying its expertise in artificial intelligence and multiomics analysis to examine the longitudinal plasma samples. This analytical approach combines sophisticated proteomics technology with data integration.The Chronos-PD team will utilize advanced proprietary computational methods to process the complex datasets generated from the plasma analyses, which include thousands of proteins per sample. Crucially, this will allow for the study of protein changes over time with unprecedented detail and the identification of subtle changes that may indicate warning signs of disease onset.This methodology extends beyond simple protein identification. It incorporates machine learning algorithms designed to recognize patterns across multiple protein markers and time points. This enables researchers to examine not just individual biomarkers but also the complex interactions between different proteins and their changes over time. Going back in time to search for the first signs of Parkinson’s disease, even before symptoms appear, has the potential to revolutionize disease management. Our goal is to accelerate and ultimately develop new diagnostics and disease-modifying therapies that could mitigate or even prevent its manifestation. Our vision is for this platform to continue growing in terms of knowledge, collaborations, and its capacity to help society advance in the fight against some of the world’s most urgent public health challenges.Dr. Jörg Schüttrumpf , Chief Scientific Innovation Officer, GrifolsBeyond Parkinson\'s: What this means for future researchGrifols’ plasma repository, which includes samples representing thousands of disease states, provides opportunities to apply similar analytical approaches to other neurological conditions and diseases across various therapeutic areas.The pilot study is anticipated to be completed by the first half of 2025. As the research program progresses, researchers will continue to explore additional applications of their plasma repository and analytical capabilities, thus advancing understanding of various diseases and potential treatment approaches.Through these efforts, Grifols is striving to advance patient care and the development of more effective therapeutic strategies. The insights gained from this research could be the catalyst for a series of major breakthroughs.Dr. Schüttrumpf will discuss the Chronos-PD initiative at the upcoming Reuters Pharma 2025 conference in Barcelona, April 9-11.

$Grifols, through pioneering plasma research, looks to reveal early warning signs of Parkinson\'s$

100 项与 Human plasma-derived fibrinolysin (Grifols) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
动脉闭塞	临床2期	美国	Grifols Therapeutics, Inc.	2010-12-01
动脉闭塞	临床2期	比利时	Grifols Therapeutics, Inc.	2010-12-01
动脉闭塞	临床2期	保加利亚	Grifols Therapeutics, Inc.	2010-12-01
动脉闭塞	临床2期	捷克	Grifols Therapeutics, Inc.	2010-12-01
动脉闭塞	临床2期	德国	Grifols Therapeutics, Inc.	2010-12-01
动脉闭塞	临床2期	印度	Grifols Therapeutics, Inc.	2010-12-01
动脉闭塞	临床2期	秘鲁	Grifols Therapeutics, Inc.	2010-12-01
动脉闭塞	临床2期	波兰	Grifols Therapeutics, Inc.	2010-12-01
动脉闭塞	临床2期	罗马尼亚	Grifols Therapeutics, Inc.	2010-12-01
动脉闭塞	临床2期	塞尔维亚	Grifols Therapeutics, Inc.	2010-12-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01222117 (Pubmed)	临床2期	动脉闭塞	174	150 mg plasmin without BOC	願齋鏇簾蓋願醖廠醖繭(觸積簾繭築獵淵糧顧觸) = 構鹹憲遞窪廠襯製廠齋衊築憲廠壓觸夢艱製鬱 (積鹹選壓鏇廠構蓋繭蓋 ) 更多	-	2019-01-01
				rtPA without BOC	憲鹹壓積鹹網築艱願憲(膚選壓餘鏇餘顧簾顧簾) = 廠願夢簾選鬱鬱夢選齋遞鏇構餘壓獵觸繭網顧 (網膚壓觸襯壓淵願齋獵 ) 更多
NCT01014975 (CTgov)	临床1/2期	大脑中动脉梗塞 \| 急性缺血性卒中	40	Plasmin (Human) (20 mg Plasmin (Human))	獵餘遞衊憲衊窪範鬱觸 = 廠鏇製餘齋簾範糧願窪廠糧膚製夢淵夢選鬱選 (膚壓積衊築糧鑰網製膚, 膚鹹鹹鏇鬱簾餘網鏇範 ~ 醖膚衊窪蓋築艱鬱鹽蓋) 更多	-	2015-10-21
				Plasmin (Human) (40 mg Plasmin (Human))	獵餘遞衊憲衊窪範鬱觸 = 膚網遞願艱廠膚壓積簾廠糧膚製夢淵夢選鬱選 (膚壓積衊築糧鑰網製膚, 淵淵鬱憲鑰築繭膚網鹹 ~ 願顧蓋築夢淵淵積醖範) 更多